DIRS.INFO The most relevant business & tech news

☆ Harvard-trained neuroscientist with 20+ years experience: 7 tricks I use to keep my memory sharp
▼ + stars: | 2024-03-19 | by ( Lisa Genova | ) www.cnbc.com time to read: +7 min

See itWhen you create a mental image of what you're trying to remember, you add more neural connections to it. Make what you're trying to remember something you can easily see in your mind's eye2. Use your imaginationPeople with the best memories have the best imaginations. People with the best memories have the best imaginations. If you don't get enough sleep, you'll go through the next day experiencing a form of amnesia.

Persons: Dwayne, Johnson, Lisa Genova, Taylor, aren't, you'll, Lisa Organizations: Harvard, New York Times, Bates College, Harvard University, PBS, NBC, CNN, NPR, TED, CNBC Locations: biopsychology

☆ 'This is the mental health moment': Innovation and M&A are helping to boost these stocks to new heights
▼ + stars: | 2024-02-19 | by ( Michelle Fox | ) www.cnbc.com time to read: +14 min

There's been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Attention to a long-time crisis The mental health crisis is nothing new. However, there has also been a growing awareness and acceptance of mental health illnesses over the past decade, said Canaccord Genuity analyst Richard Close. "There's been recognition that mental health has a significant impact on a person's overall health," he said. "This is the mental health moment," said Dr. Ken Duckworth, NAMI's chief medical officer and author of "You Are Not Alone: The NAMI Guide to Mental Health."

Persons: There's, Covid, Peter Micca, AbbVie, Emraclidine, Myers Squibb, Karuna, Marc Goodman, Canaccord, Richard Close, MacKenzie Scott, Ken Duckworth, NAMI, Deloitte's Micca, William Blair, Myles Minter, Minter, Auvelity, Leerink's Goodman, Ashwani Verma, Verma, Goodman, BioHaven, Cerevel, Neumora, tardive, David Song, BetterHelp, psychedelics Johnson, Johnson, Spravato, Blair's Minter, Axsome, Micca, Michael Bloom Organizations: Institute for Health Metrics, Deloitte, Cerevel Therapeutics, Karuna Therapeutics, Bristol Myers, Leerink Partners, Centers for Disease Control, National Alliance, Mental, Mental Health, Wall Street, Therapeutics, Neumora Therapeutics, UBS, Karuna, Cellular Therapies, Xenon Pharmaceuticals, Neurocrine Biosciences, Acadia Pharmaceuticals, Tema Neuroscience, Axsome Therapeutics, Acadia Healthcare, BetterHelp, CNBC, pharma, Cellular Locations: Covid, Bristol, XEN1101, Acadia, Tema

☆ Ambitious research yields new atlas of human brain cells
▼ + stars: | 2023-10-12 | by ( Will Dunham | ) www.reuters.com time to read: +5 min

The human brain is complex in terms of its utility - sensing, moving, reading, writing, speaking, thinking and more - and its cellular diversity. The research identified 3,313 cell types, roughly 10 times more than previously known, and the complete set of genes used by each cell type while also mapping their regional distribution in the brain. "The brain cell atlas as a whole provides the cellular substrate for everything that we can do as human beings," said neuroscientist Ed Lein of the Seattle-based Allen Institute for Brain Science, one of the researchers. The various cell types have distinct properties and are likely affected differently in disease, Lein said. "We are only at the very beginning of delineating the complexity of the human brain," said another of the researchers, Bing Ren, director of the University of California, San Diego Center for Epigenomics.

Persons: Denis Balibouse, Ed Lein, Lein, Trygve Bakken, Bing Ren, Will Dunham, Rosalba O'Brien Organizations: Belle Idee University, REUTERS, Rights, U.S, government's National Institutes of Health, Census Network, Allen Institute for Brain Science, Allen, University of California, San Diego Center for Epigenomics, Thomson Locations: Neuropsychiatry, Chene, Bourg, Geneva, Seattle

☆ PMS now could mean more than twice the risk of early menopause later, study shows
▼ + stars: | 2023-09-20 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +5 min

Menopause is considered early when it occurs before age 45, which will happen in 5% to 10% of women, Yang said. Early menopause is concerning because of the shortened reproductive years, but also because of links to other health concerns, she added. A 2010 study found that women who experience early menopause are at an increased risk for overall mortality, including cardiovascular diseases, osteoporosis and neurological diseases. How are PMS and early menopause connected? Women also need to know that there are ways to manage early menopause and the bothersome hot flashes, she said.

Persons: ”, Yihui Yang, Yang, Stephanie Faubion, Faubion, —, Donghao Lu, ” Faubion, Elizabeth Bertone, Johnson, “ Organizations: CNN, Karolinska Institutet, Mayo Clinic Center, Women’s Health, PMDs, Karolinska, University of Massachusetts Amherst, American College of Obstetricians, Women’s, US Department of Health, Human Services Locations: Sweden

☆ Astronauts’ brains take a hit during long spaceflights
▼ + stars: | 2023-06-08 | by ( Ashley Strickland | ) edition.cnn.com time to read: +5 min

CNN —Spaceflights lasting six months or longer take a toll on the brains of astronauts, and crew members may need to wait at least three years before returning to space, according to new research. Scientists compared the brain scans of 30 astronauts taken before spaceflights lasting two weeks, six months or a year with scans taken after they returned to Earth. During the analysis, the researchers determined that the degree to which the ventricles enlarged varied depending on how long the astronauts were in space. Seven of the astronauts with a shorter period of recovery between missions showed little ventricular enlargement after their most recent flight. However, astronauts have very specialized skill sets and training and there may be rationale to include them on additional missions before this time.”

Persons: CNN —, Artemis, ”, Rachael Seidler, Seidler, ” Seidler Organizations: CNN, International, Station, NASA, University of Florida, UF, Norman Fixel Institute, Neurological Diseases, “ Locations: ”

☆ Grimes said she got a brain gadget for her birthday from a company competing with Elon Musk's Neuralink
▼ + stars: | 2023-03-22 | by ( Grace Kay | Hilary Brueck | ) www.businessinsider.com time to read: +5 min

Neurosity's device is designed to help people focus, but some developers are using it as a BCI. "Getting a non invasive brain computer interface for my birthday (!!!!? Grimes' birthday 'Crown' measures brain activity, and is designed to help people focusNeurosity's headset uses electroencephalogram technology, or EEG, to measure brain activity by placing small metal electrodes on a person's scalp. In a now-deleted tweet, the singer said Neurosity's device allowed her to use her mind to move a cursor. Meanwhile, Neurosity's device is already on the market.

☆ What Covid taught scientists and the public about the flu
▼ + stars: | 2022-11-21 | by ( Caroline Hopkins | Nbc News Contributor Caroline Hopkins Is A Health | Science Journalist Who Covers Cancer Treatment For Precision Oncology News. She Is A Graduate Of The Columbia University Graduate School Of Journalism. | ) www.nbcnews.com time to read: +10 min

Flu transmission can be stoppedThe 2020-2021 flu season — the first full flu season of the Covid pandemic — defied Tedros’ message. ‘Nonpharmaceutical interventions’ workBefore Covid, experts put limited stock in so-called nonpharmaceutical — that is, nonvaccination — strategies for preventing flu transmission. Although the airline case study taught the research community about airborne flu transmission, she said the general public’s appreciation for these risks has increased because of Covid. In that study, the researchers compared mild Covid infections with mild flu infections in mice and humans and found that the brain effects were similar around seven days post-infection. Asymptomatic flu infections may be underappreciatedThe Covid pandemic put a spotlight on the extent and risk of asymptomatic infections.

☆ The success of Biogen's new Alzheimer's drug could be the start of a redemption arc for the biotech — and boost rivals racing to develop similar treatments
▼ + stars: | 2022-09-28 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +3 min

Biotech companies Biogen and Eisai just released data on their new Alzheimer's drug. Initial results of a highly anticipated test of an Alzheimer's drug, called lecanemab, were released on Tuesday evening by biotech firms Biogen and Eisai. "While the market has been skeptical of lecanemab's prospects, the trial appears to be a resounding success," Cowen analysts said. An earlier Alzheimer's drug developed by Biogen and Eisai, Aduhelm, also acts on beta-amyloid. Mizhuo analyst Graig Suvannavejh, said that the lecanemab results are "a key potential positive catalyst for companies" working to develop Alzheimer's treatments.

☆ Biogen and Eisai's latest clinical trial just crossed the finish line. Here's why analysts say the results could disrupt the future of Alzheimer's care.
▼ + stars: | 2022-09-28 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +7 min

It's a complicated, debilitating illness and drug companies have struggled for years to come up with viable treatments. On Tuesday September 27, Biogen and Eisai announced that lecanemab slowed the rate of cognitive decline in Alzheimer's patients by 27%. Analysts say that this positive result could lead to it becoming a blockbuster drug for the companies. Other big drug companies such as Roche Holdings and Eli Lilly are pursuing similar treatments, with results expected to come later this year and early next year, respectively. "I think people's confidence in the amyloid hypothesis would go down even further, but ultimately people would wait to see what those other data events show," he said.

☆ Biogen's latest clinical trial is inching towards the finish line. Here's why analysts say the results could disrupt the future of Alzheimer's care.
▼ + stars: | 2022-09-19 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +7 min

It's a complicated, debilitating illness and drug companies have struggled for years to come up with viable treatments. Other big drug companies such as Roche Holdings and Eli Lilly are pursuing similar treatments, with results expected to come later this year and early next year, respectively. "I think people's confidence in the amyloid hypothesis would go down even further, but ultimately people would wait to see what those other data events show," he said. Negative results might give a boost to companies that are exploring alternate ways to treat Alzheimer's disease. And though Biogen's drug is furthest along in development, it's far from being the only treatment being tested for Alzheimer's.

☆ Meet the 10 neuroscience startups that have raised millions to treat mental health and cure neurologic diseases
▼ + stars: | 2022-09-13 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +2 min

In 2021, private biotech firms targeting neurological diseases raised $2.61 billion from investors. Here are the 10 neuroscience startups that have raised the most cash to date. The field languished for years after a host of prospective treatments for neurological diseases failed to come to market. That year, neuroscience companies raised $2.61 billion from venture capitalists. Here are the 10 biotech startups that have raised the most money to develop drugs for neurological diseases, listed by amount raised:

Search resuls for: "Neurological Diseases"

11 mentions found